Advantage Alpha Capital Partners LP Trims Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Advantage Alpha Capital Partners LP reduced its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 39.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,447 shares of the biopharmaceutical company’s stock after selling 8,932 shares during the quarter. Advantage Alpha Capital Partners LP’s holdings in TG Therapeutics were worth $405,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Arizona State Retirement System grew its holdings in shares of TG Therapeutics by 0.9% in the fourth quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company’s stock valued at $1,283,000 after purchasing an additional 364 shares during the period. Blue Trust Inc. boosted its holdings in TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 371 shares during the last quarter. Brookstone Capital Management grew its stake in shares of TG Therapeutics by 3.7% in the 4th quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company’s stock valued at $527,000 after buying an additional 624 shares during the period. Daymark Wealth Partners LLC increased its holdings in shares of TG Therapeutics by 1.7% during the 4th quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company’s stock worth $1,249,000 after buying an additional 689 shares during the last quarter. Finally, New York State Teachers Retirement System raised its position in shares of TG Therapeutics by 1.9% during the 4th quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company’s stock valued at $1,317,000 after buying an additional 837 shares during the period. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Price Performance

TGTX stock opened at $42.61 on Tuesday. The business’s fifty day moving average price is $33.47 and its 200 day moving average price is $29.89. TG Therapeutics, Inc. has a 12-month low of $12.93 and a 12-month high of $43.32. The company has a market capitalization of $6.69 billion, a PE ratio of -426.06 and a beta of 2.30. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. The business had revenue of $108.19 million for the quarter, compared to analysts’ expectations of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. On average, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, TG Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $40.67.

Insider Buying and Selling at TG Therapeutics

In other news, CFO Sean A. Power sold 11,337 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the sale, the chief financial officer now directly owns 670,632 shares in the company, valued at approximately $20,313,443.28. This trade represents a 1.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.50% of the stock is currently owned by corporate insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.